Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Symptom severity
RCT 3-armed trial	25 treatment-resistant people	Brief Psychiatric Scale (BPRS) total score baseline and 12 weeks with quetiapine (mean dose 463.6 mg/day) with fluphenazine (mean dose 13.2 mg/day)	Quetiapine 53.50 at baseline v 53.83 at 12 weeks Fluphenazine 54.69 at baseline v 51.85 at 12 weeks P greater-than or equal to 0.05 for difference in change from baseline		Not significant
RCT 3-armed trial	25 treatment-resistant people	Clinical Global Impression scale (CGI) Severity score baseline and 12 weeks with quetiapine (mean dose 463.6 mg/day) with fluphenazine (mean dose 13.2 mg/day)	Quetiapine 5.33 at baseline v 5.18 at 12 weeks Fluphenazine 5.38 at baseline v 5.15 at 12 weeks P greater-than or equal to 0.05 for difference in change from baseline		Not significant
RCT 3-armed trial	25 treatment-resistant people	Change from baseline in BPRS positive symptom score 12 weeks –0.67 with quetiapine (mean dose 463.6 mg/day) –0.92 with fluphenazine (mean dose 13.2 mg/day)	P greater-than or equal to 0.05 for difference in change from baseline		Not significant
RCT 3-armed trial	25 treatment-resistant people	Change from baseline in BPRS negative symptom score 12 weeks +0.42 with quetiapine (mean dose 463.6 mg/day) –0.23 with fluphenazine (mean dose 13.2 mg/day)	P value not reported